磷脂酰肌醇 3-激酶-AKT-雷帕霉素靶蛋白（PI3K-Akt-mTOR）信号通路在非小细胞肺癌中的作用。
Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer.
机构信息
1 Department of Medical Oncology, Chris O'Brien Lifehouse, Camperdown, NSW, Australia ; 2 Department of Medical Oncology, Macarthur Cancer Therapy Centre, Campbelltown, NSW, Australia.
出版信息
Transl Lung Cancer Res. 2015 Apr;4(2):165-76. doi: 10.3978/j.issn.2218-6751.2015.01.04.
Abstract
Non-small cell lung cancer (NSCLC) is a devastating disease with poor prognosis. Systemic chemotherapy has been the mainstay of treatment in advanced disease for many decades. Personalized targeted therapy such as epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) and crizotinib has significantly changed the treatment paradigm in NSCLC. The future success of development of molecular targeted therapy relies on the understanding of signal transduction pathways. The PI3K-Akt-mTOR pathway is commonly deregulated in human malignancy including NSCLC. Therefore, this pathway is a target for many therapeutic developments. This review will provide an overview of PI3K-Akt-mTOR signaling pathway, genetic alterations activating the pathway and clinical therapeutic development of pathway inhibitors.
摘要
非小细胞肺癌（NSCLC）是一种预后不良的毁灭性疾病。几十年来，系统化疗一直是晚期疾病的主要治疗方法。表皮生长因子受体酪氨酸激酶抑制剂（EGFR TKIs）和克唑替尼等个性化靶向治疗已显著改变了 NSCLC 的治疗模式。分子靶向治疗的未来成功取决于对信号转导途径的理解。PI3K-Akt-mTOR 途径在包括 NSCLC 在内的人类恶性肿瘤中通常失调。因此，该途径是许多治疗开发的目标。本文综述了 PI3K-Akt-mTOR 信号通路、激活该通路的遗传改变以及通路抑制剂的临床治疗进展。
相似文献
1
Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer.磷脂酰肌醇 3-激酶-AKT-雷帕霉素靶蛋白（PI3K-Akt-mTOR）信号通路在非小细胞肺癌中的作用。
Transl Lung Cancer Res. 2015 Apr;4(2):165-76. doi: 10.3978/j.issn.2218-6751.2015.01.04.
2
Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.针对磷脂酰肌醇 3-激酶 (PI3K)/AKT/哺乳动物雷帕霉素靶蛋白 (mTOR) 通路：治疗鳞状细胞肺癌的新兴策略。
Cancer Treat Rev. 2014 Sep;40(8):980-9. doi: 10.1016/j.ctrv.2014.06.006. Epub 2014 Jul 3.
3
Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.表皮生长因子受体抑制剂耐药的非小细胞肺癌治疗中 PI3K/Akt/mTOR 通路抑制剂的临床前原理。
Clin Lung Cancer. 2013 Jul;14(4):322-32. doi: 10.1016/j.cllc.2012.12.001. Epub 2013 Jan 16.
4
The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.双重 PI3K/mTOR 抑制剂 BEZ235 可限制肺癌肿瘤的生长，而与 EGFR 状态无关，是联合治疗方案中的有力辅助药物。
J Exp Clin Cancer Res. 2019 Jul 1;38(1):282. doi: 10.1186/s13046-019-1282-0.
5
Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer.针对非小细胞肺癌中的 PI3K/AKT/mTOR 通路。
Biochem Pharmacol. 2014 Aug 1;90(3):197-207. doi: 10.1016/j.bcp.2014.05.011. Epub 2014 May 24.
6
Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.PI3K/AKT/mTOR 通路中癌症治疗的分子靶点。
Pharmacol Ther. 2014 May;142(2):164-75. doi: 10.1016/j.pharmthera.2013.12.004. Epub 2013 Dec 9.
7
Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer.PI3K/AKT/mTOR 通路抑制剂的研发及其在非小细胞肺癌个体化治疗中的应用。
J Thorac Oncol. 2012 Aug;7(8):1315-26. doi: 10.1097/JTO.0b013e31825493eb.
8
Polyphyllin II Restores Sensitization of the Resistance of PC-9/ZD Cells to Gefitinib by a Negative Regulation of the PI3K/Akt/mTOR Signaling Pathway.重楼皂苷II通过负调控PI3K/Akt/mTOR信号通路恢复PC-9/ZD细胞对吉非替尼的耐药敏感性。
Curr Cancer Drug Targets. 2017;17(4):376-385. doi: 10.2174/1568009616666161213141608.
9
New development of inhibitors targeting the PI3K/AKT/mTOR pathway in personalized treatment of non-small-cell lung cancer.靶向PI3K/AKT/mTOR通路的抑制剂在非小细胞肺癌个体化治疗中的新进展
Anticancer Drugs. 2015 Jan;26(1):1-14. doi: 10.1097/CAD.0000000000000172.
10
The activity of a PI3K δ-sparing inhibitor, MEN1611, in non-small cell lung cancer cells with constitutive activation of the PI3K/AKT/mTOR pathway.PI3K δ保留抑制剂MEN1611在PI3K/AKT/mTOR通路组成性激活的非小细胞肺癌细胞中的活性。
Front Oncol. 2023 Nov 14;13:1283951. doi: 10.3389/fonc.2023.1283951. eCollection 2023.
引用本文的文献
1
Comprehensive computational analysis via Adverse Outcome Pathways and Aggregate Exposure Pathways in exploring synergistic effects from radon and tobacco smoke on lung cancer.通过不良结局途径和累积暴露途径进行综合计算分析，以探索氡气和烟草烟雾对肺癌的协同作用。
Front Public Health. 2025 Jul 31;13:1571290. doi: 10.3389/fpubh.2025.1571290. eCollection 2025.
2
High frequency of the PIK3CA H1047L mutation in Indonesian breast cancer across molecular subtypes.印度尼西亚乳腺癌各分子亚型中PIK3CA H1047L突变的高频率。
PLoS One. 2025 May 5;20(5):e0322154. doi: 10.1371/journal.pone.0322154. eCollection 2025.
3
The polyphenolic compound, α-conidendrin, exerts anti-colon cancer and anti-angiogenic effects by targeting several signaling molecules.多酚类化合物α-松柏苷通过作用于多种信号分子发挥抗结肠癌和抗血管生成作用。
Naunyn Schmiedebergs Arch Pharmacol. 2025 Apr 10. doi: 10.1007/s00210-025-04090-2.
4
The Role of the Sirtuin Family Histone Deacetylases in Acute Myeloid Leukemia-A Promising Road Ahead.沉默调节蛋白家族组蛋白去乙酰化酶在急性髓系白血病中的作用——前路光明。
Cancers (Basel). 2025 Mar 17;17(6):1009. doi: 10.3390/cancers17061009.
5
Reverse-engineering the FLT3-PI3K/AKT axis to enhance TILs function and improve prognosis in ovarian and cervical cancers.逆向工程FLT3-PI3K/AKT轴以增强肿瘤浸润淋巴细胞功能并改善卵巢癌和宫颈癌的预后。
J Ovarian Res. 2025 Jan 25;18(1):14. doi: 10.1186/s13048-025-01592-8.
6
Circular RNA ATP9A Stimulates Non-small Cell Lung Cancer Progression via MicroRNA-582-3p/Ribosomal Protein Large P0 Axis and Activating Phosphatidylinositol 3-Kinase/Protein Kinase B Signaling Pathway.环状RNA ATP9A通过微小RNA-582-3p/核糖体蛋白大亚基P0轴并激活磷脂酰肌醇3-激酶/蛋白激酶B信号通路刺激非小细胞肺癌进展。
Appl Biochem Biotechnol. 2025 May;197(5):3166-3183. doi: 10.1007/s12010-024-05159-z. Epub 2025 Jan 20.
7
PI3K/mTOR Inhibitor VS-5584 Alters Expression of WNT Signaling Genes and Induces Apoptosis in Lung Adenocarcinoma Cells: In Vitro and In Silico Insight.PI3K/mTOR抑制剂VS-5584改变WNT信号基因的表达并诱导肺腺癌细胞凋亡：体外和计算机模拟研究
Cell Biochem Biophys. 2025 Jun;83(2):2313-2322. doi: 10.1007/s12013-024-01643-9. Epub 2024 Dec 17.
8
Analysis of Modular Hub Genes and Therapeutic Targets across Stages of Non-Small Cell Lung Cancer Transcriptome.非小细胞肺癌转录组各阶段的模块化枢纽基因与治疗靶点分析。
Genes (Basel). 2024 Sep 25;15(10):1248. doi: 10.3390/genes15101248.
9
miR-30c-5p inhibits esophageal squamous cell carcinoma progression by repressing the PI3K/AKT signaling pathway.miR-30c-5p 通过抑制 PI3K/AKT 信号通路抑制食管鳞状细胞癌进展。
Thorac Cancer. 2024 Oct;15(30):2206-2216. doi: 10.1111/1759-7714.15427. Epub 2024 Sep 17.
10
The safety and efficacy of binimetinib for lung cancer: a systematic review.比尼替尼治疗肺癌的安全性和疗效：系统评价。
BMC Pulm Med. 2024 Aug 1;24(1):379. doi: 10.1186/s12890-024-03178-4.
本文引用的文献
1
Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study.布帕利昔布（BKM120）用于PI3K通路激活的非小细胞肺癌患者的安全性和有效性：II期BASALT-1研究结果
J Thorac Oncol. 2015 Sep;10(9):1319-1327. doi: 10.1097/JTO.0000000000000607.
2
Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.针对磷脂酰肌醇 3-激酶 (PI3K)/AKT/哺乳动物雷帕霉素靶蛋白 (mTOR) 通路：治疗鳞状细胞肺癌的新兴策略。
Cancer Treat Rev. 2014 Sep;40(8):980-9. doi: 10.1016/j.ctrv.2014.06.006. Epub 2014 Jul 3.
3
Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.一项针对晚期实体瘤患者的I期剂量递增和扩展研究，该研究使用口服泛I类PI3K抑制剂布帕利西布（BKM120）。
Invest New Drugs. 2014 Aug;32(4):670-81. doi: 10.1007/s10637-014-0082-9. Epub 2014 Mar 21.
4
Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway.鉴定影响 PI3K 通路的不同遗传改变的肿瘤模型中 PI3K/mTOR 抑制剂 XL765（SAR245409）的活性。
Mol Cancer Ther. 2014 May;13(5):1078-91. doi: 10.1158/1535-7163.MCT-13-0709. Epub 2014 Mar 14.
5
Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors.PI3K/mTOR 抑制剂 SAR245409（XL765）联合厄洛替尼治疗晚期实体瘤患者的 I 期安全性和药代动力学研究。
J Thorac Oncol. 2014 Mar;9(3):316-23. doi: 10.1097/JTO.0000000000000088.
6
Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors.Buparlisib（BKM120），一种口服全类 I PI3K 抑制剂，在日本晚期实体瘤患者中的 I 期剂量递增研究。
Cancer Sci. 2014 Mar;105(3):347-53. doi: 10.1111/cas.12350. Epub 2014 Feb 13.
7
Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer.依维莫司联合厄洛替尼治疗晚期非小细胞肺癌患者的 II 期研究。
Ann Oncol. 2014 Feb;25(2):409-15. doi: 10.1093/annonc/mdt536. Epub 2013 Dec 23.
8
Phosphorylated Akt expression is a prognostic marker in early-stage non-small cell lung cancer.磷酸化 Akt 表达是早期非小细胞肺癌的预后标志物。
J Clin Pathol. 2014 Apr;67(4):333-40. doi: 10.1136/jclinpath-2013-201870. Epub 2013 Nov 21.
9
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.III 期研究阿法替尼或顺铂加培美曲塞治疗 EGFR 突变的转移性肺腺癌患者。
J Clin Oncol. 2013 Sep 20;31(27):3327-34. doi: 10.1200/JCO.2012.44.2806. Epub 2013 Jul 1.
10
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.克唑替尼与化疗用于治疗晚期 ALK 阳性肺癌。
N Engl J Med. 2013 Jun 20;368(25):2385-94. doi: 10.1056/NEJMoa1214886. Epub 2013 Jun 1.
Zotero 插件